Načítá se...
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
BACKGROUND: The high cost and prolonged timeline of new drug discovery and development are major roadblocks to creating therapies for infectious diseases. Candida albicans is an opportunistic fungal pathogen that is the most common cause of fatal fungal infections in humans and costs $2–4 billion do...
Uloženo v:
| Vydáno v: | Ann Clin Microbiol Antimicrob |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4462072/ https://ncbi.nlm.nih.gov/pubmed/26054754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12941-015-0090-4 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|